Efferon® LPS

NEXT-GENERATION EXTRACORPOREAL ADSORBER. CE MARK UNDER EU MDR REQUIREMENTS.

- **Surface-modified hypercrosslinked polystyrene beads**
- **Direct removal of dissimilar therapeutic targets: endotoxins and cytokines**
- **Clinical benefits in sepsis patients validated in mRCT**

INDICATIONS:

- Sepsis and septic shock.
- Elevated levels of endotoxin in blood, critical endotoxemia.
- Elevated levels of cytokines in blood, «cytokine storm» syndrome.

MODE OF ACTION:

Multimodal adsorbent beads selectively bind two dissimilar therapeutic targets: endotoxins and excess of inflammatory mediators (such as cytokines).

Bacterial endotoxins

Endotoxins are adsorbed via interaction with surface-immobilized synthetic LPS-selective ligand.



Cytokines and cell debris are adsorbed via intrinsic porosity of hypercrosslinked polystyrene matrix.

Cytokines and inflammatory mediators

mail@efferon.com | Efferon OÜ, Mooni tn. 18, Tallinn 10613 Estonia

Efferon LPS safety and efficacy was studied in LASSO mRCT (NCT 04827407), its results were published in Shock peer-reviewed journal. Patients with abdominal sepsis, complicated with septic shock (n=58) were randomized in two groups. Control group received standard of care treatment, intervention group received two Efferon LPS hemoperfusions.

KEY BENEFITS OF EFFERON LPS HEMOPERFUSION:

- Successful resolution of septic shock and restoration of systemic hemodynamic function with lower dosage of vasopressor drugs;
- More IMV- and RRT-free days;
- Multiple Organ Failure Syndrome faster resolution;
- Oxygen metabolism function improvement;
- Reduction of endotoxemia and systemic inflammation biomarkers levels;
- No hemoperfusion-related adverse effects, less then 2% premature circuit clotting occurence.

Hospital discharge



Septic shock resolution



SOFA



Mechanical ventilation weaning



Shock 59(6), p. 846-854, June 2023.